They mention local and global partners. Would I be right in saying that these could be two separate sources of investment? The local partners get the Australian market. Global partner (I'll assume it is US from the location of the presentation) gets the USA. If they could get two licensing deals with upfront payments, that could solve many issues.
when is early 2025? If discussions are expected to conclude in Early 2025, by my definition, that is the first quarter. By the end of March, maybe April at the latest. Then it becomes Mid 2025.
If you go back a while, they said they were looking at using a partner to commercialize the product in Australia and then license out ROW rights separately.
Unfortunately, AVE is now in a less than ideal position (what's new!). The plan has been to finalise deals based on the interim trial data, which it had been hoped would already be available by now. But that data is still some way off, even with new clinical sites being added and some recruitment criteria being relaxed. And as the money is running out, decisions will have to be made before the interim data comes to hand.
I’m expecting a decision will need to be made this quarter on whether or not they partner at this premature stage. Obviously, any deal done this quarter won’t be as attractive as any deal done post-interim results, if those results are positive. Also, I would think there would be fewer offers on the table at this point as there will be potential partners who simply won’t commit until after early data is available.
In terms of who prospective partners might be, it has been stated before that interest has come from a range of groups.
The first group is Australian pharmacy chains, who would be seeking to market AVE’s CBD capsule under their own brand.
The second is Australian generic pharmas.
The third is global generic pharma/consumer health.
Finally, there are larger global pharma whose interest is more in a prescription product.
Is this activity the result of the new director? Could be a great appointment.
It could be, but as Paul has said, discussions have been happening over 3 years. Everyone will have been waiting for the data before signing. But, as we know….
If there is a deal, I believe it signals that Paul has some indication of the early results. A deal is not just a positive in terms of money but I believe it is the double whammy of positive results. Paul would have had to have figures to "sell" to the investors.
No, the trial is blinded and Paul will not have any indication of early results and so he won’t have figures at this stage to sell to investors. That’s the key problem.
is the continually advancing licensing agreement for cbd capsules separate to the clinical trial and if so isn't it about time to say yes to someone.
Only the urgent need for money makes this the time to say yes to someone because any major licensing agreement for the CBD capsule is linked to the current clinical trial.
Ideally, any deal done at this stage would be for a product not linked to the current clinical trial.
AVE Price at posting:
0.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)